Table S1 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

Key Points

• Synergistic effects were observed when targeting both Bcl-xL and Mcl-1 in CRPC models, indicating enhanced treatment potential.
• The study reported IC50 values for BH3 mimetics as single agents in 2D models, showcasing their potential efficacy.
• Assessment using BH3 mimetics demonstrated enhanced anti-cancer effects on AR-V7-expressing CRPC tumors.
• Findings support the need for combination treatments targeting Bcl-xL and Mcl-1 to optimize therapy in CRPC models.